18 May 2013
Keywords: kosan, starts, trials, kos-1022, kos, cancer, therapy
Article | 30 January 2006
US drugmaker Kosan Biosciences says it has initiated a Phase I multicenter trial of KOS-1022, its second-generation heat shock protein
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
30 January 2006
17 May 2013
© 2013 thepharmaletter.com